These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8740842)
41. Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Khunamornpong S; Lerwill MF; Siriaunkgul S; Suprasert P; Pojchamarnwiputh S; Chiangmai WN; Young RH Int J Gynecol Pathol; 2008 Jul; 27(3):366-79. PubMed ID: 18580314 [TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct. Suto T; Sugai T; Nakamura S; Uesugi N; Sasaki R; Kanno S; Saito K Oncology; 1997; 54(5):407-13. PubMed ID: 9260603 [TBL] [Abstract][Full Text] [Related]
43. p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction. Kasuya K; Nagakawa Y; Matsudo T; Ozawa T; Tsuchida A; Aoki T; Itoi T; Itokawa F J Hepatobiliary Pancreat Surg; 2009; 16(3):376-81. PubMed ID: 19183832 [TBL] [Abstract][Full Text] [Related]
44. Prognostic value of p53 and Ki-67 expression in resected or biopsy specimens of bile duct carcinoma. Murakami M; Sasaki T; Kuwada Y; Yamasaki S; Kuwahara K; Chayama K Oncol Rep; 2003; 10(5):1091-6. PubMed ID: 12883663 [TBL] [Abstract][Full Text] [Related]
45. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Argani P; Shaukat A; Kaushal M; Wilentz RE; Su GH; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH Cancer; 2001 Apr; 91(7):1332-41. PubMed ID: 11283934 [TBL] [Abstract][Full Text] [Related]
46. The extrahepatic bile duct lesions in end-stage primary sclerosing cholangitis. Katabi N; Albores-Saavedra J Am J Surg Pathol; 2003 Mar; 27(3):349-55. PubMed ID: 12604891 [TBL] [Abstract][Full Text] [Related]
47. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210 [TBL] [Abstract][Full Text] [Related]
48. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts. Minato H; Nakanuma Y; Terada T Histopathology; 1996 May; 28(5):411-9. PubMed ID: 8735716 [TBL] [Abstract][Full Text] [Related]
49. Albumin In Situ Hybridization Can Be Positive in Adenocarcinomas and Other Tumors From Diverse Sites. Nasir A; Lehrke HD; Mounajjed T; Said S; Zhang L; Yasir S; Shah SS; Chandan VS; Smyrk TC; Moreira RK; Boland Froemming JM; Herrera Hernandez LP; Wu TT; Graham RP Am J Clin Pathol; 2019 Jul; 152(2):190-199. PubMed ID: 31107526 [TBL] [Abstract][Full Text] [Related]
50. Increasing expression of gastrointestinal phenotypes and p53 along with histologic progression of intraductal papillary neoplasia of the liver. Shimonishi T; Zen Y; Chen TC; Chen MF; Jan YY; Yeh TS; Nimura Y; Nakanuma Y Hum Pathol; 2002 May; 33(5):503-11. PubMed ID: 12094375 [TBL] [Abstract][Full Text] [Related]
51. [Tumor grading of the hepatobiliary system]. Jütte H; Tannapfel A Pathologe; 2016 Jul; 37(4):299-303. PubMed ID: 27342594 [TBL] [Abstract][Full Text] [Related]
52. Altered p21(WAF1/CIP1) expression is associated with poor prognosis in extrahepatic bile duct carcinoma. Li X; Hui A; Takayama T; Cui X; Shi Y; Makuuchi M Cancer Lett; 2000 Jun; 154(1):85-91. PubMed ID: 10799743 [TBL] [Abstract][Full Text] [Related]
53. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Tannapfel A; Engeland K; Weinans L; Katalinic A; Hauss J; Mössner J; Wittekind C Br J Cancer; 1999 Jun; 80(7):1069-74. PubMed ID: 10362118 [TBL] [Abstract][Full Text] [Related]
54. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859 [TBL] [Abstract][Full Text] [Related]
55. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis. Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685 [TBL] [Abstract][Full Text] [Related]
56. Alpha-fetoprotein-producing clear cell carcinoma of the extrahepatic bile ducts. Miyazawa M; Torii T; Toshimitsu Y; Kamizasa N; Suzuki T; Shinozuka N; Ishizawa K; Koyama I J Clin Gastroenterol; 2006 Jul; 40(6):555-7. PubMed ID: 16825940 [TBL] [Abstract][Full Text] [Related]
57. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Suto T; Sugai T; Nakamura S; Funato O; Nitta H; Sasaki R; Kanno S; Saito K Cancer; 1998 Jan; 82(1):86-95. PubMed ID: 9428483 [TBL] [Abstract][Full Text] [Related]
58. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Kang YK; Kim WH; Jang JJ Hum Pathol; 2002 Sep; 33(9):877-83. PubMed ID: 12378511 [TBL] [Abstract][Full Text] [Related]
59. Immunohistochemical expression of cytokeratins in intrahepatic cholangiocarcinoma and metastatic adenocarcinoma of the liver. Sasaki A; Kawano K; Aramaki M; Nakashima K; Yoshida T; Kitano S J Surg Oncol; 1999 Feb; 70(2):103-8. PubMed ID: 10084653 [TBL] [Abstract][Full Text] [Related]
60. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions. Tretiakova M; Antic T; Westerhoff M; Mueller J; Himmelfarb EA; Wang HL; Xiao SY Am J Surg Pathol; 2012 Jan; 36(1):101-8. PubMed ID: 21989348 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]